Clinical Trial Update: Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the long-term safety and efficacy of odevixibat in Alagille syndrome; the study is currently recruiting. Sponsor: Albireo, an Ipsen C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alagille Syndrome

Drugs mentioned

• Odevixibat (odevixibat)

Snippet

Sponsor: Albireo, an Ipsen Company | Conditions: Alagille Syndrome | Phase 3 | Status: RECRUITING